Curated News
By: NewsRamp Editorial Staff
November 28, 2025
Soligenix Achieves 2-Year Vaccine Stability at High Temperatures
TLDR
- Soligenix's ThermoVax platform offers a competitive edge with heat-stable vaccines that can be stockpiled for rapid deployment during outbreaks, reducing logistical costs.
- Soligenix's ThermoVax platform maintains vaccine structural integrity and immunogenicity for at least 24 months at 40°C using proprietary protein subunit technology and stabilization methods.
- Soligenix's heat-stable vaccine technology improves global health equity by enabling reliable vaccine storage in remote areas without refrigeration, saving lives during outbreaks.
- Soligenix developed vaccines that remain stable for years at scorching temperatures above 40°C, potentially transforming how we respond to deadly viruses like Ebola.
Impact - Why it Matters
This breakthrough in thermal stability technology addresses one of the biggest challenges in global vaccine distribution—the cold chain requirement that limits access in developing regions and remote areas. By enabling vaccines to remain effective for extended periods at high temperatures, Soligenix's innovation could dramatically improve outbreak response capabilities for deadly viruses like Ebola and Marburg, potentially saving countless lives during future epidemics. The technology also has broader implications for making all types of vaccines more accessible and cost-effective worldwide, representing a fundamental shift in how we approach disease prevention and pandemic preparedness.
Summary
Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company specializing in biodefense and rare disease vaccines, has achieved a significant breakthrough in vaccine stability technology. The company recently published a peer-reviewed summary demonstrating remarkable long-term high-temperature stability of its protein subunit vaccine platform targeting Ebola and Marburg-related viruses. Using its proprietary ThermoVax® platform, Soligenix has developed formulations that maintain structural integrity and immunogenicity for at least 24 months when stored at temperatures above 40°C—a capability that could revolutionize global outbreak response by eliminating the need for complex cold chain storage systems that currently limit vaccine distribution in resource-limited regions.
The scientific publication, titled 'Development of Thermostable Filovirus Vaccines Using Protein Subunit Technology,' reveals that Soligenix's stabilized filovirus vaccine antigens significantly outperformed unstabilized comparators, which degraded substantially under identical high-temperature conditions. This research, supported by ongoing U.S. government contracts with BARDA and the National Institute of Allergy and Infectious Diseases, represents a major advancement in biodefense preparedness. Beyond its filovirus vaccine programs, Soligenix's Public Health Solutions business segment also includes development of RiVax® for ricin toxin protection and CiVax™ for COVID-19 prevention, all incorporating the groundbreaking ThermoVax® technology that has been validated through extensive government-funded research and development initiatives.
In addition to its biodefense innovations, Soligenix's Specialized BioTherapeutics division is advancing multiple rare disease treatments, including HyBryte™ for cutaneous T-cell lymphoma and development programs for psoriasis, inflammatory diseases, and Behçet's disease. The company's dual focus on both public health solutions and specialized therapeutics positions it uniquely in the pharmaceutical landscape, with its thermal stabilization technology potentially transforming how vaccines are stored and distributed worldwide. For investors and stakeholders seeking the latest updates, comprehensive information about Soligenix's progress is available through the company's newsroom and corporate communications platforms.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Soligenix Achieves 2-Year Vaccine Stability at High Temperatures
